Ipsen and Exelixis, partners in developing Cabometyx (cabozantinib), have revealed that they have cut short a Phase 3 trial into the benefit of the drug in liver cancer, after the treatment hit its primary endpoints.
Ipsen ends P3 trial on liver cancer early due to strong data
